Our

Pipeline

Our Pipeline Includes Potential First- Or
Best-In-Class Molecules

Cullinan Oncology has built a diversified pipeline by identifying high-impact targets first and then pursuing the right modality. The pipeline contains assets that activate the immune system or inhibit key oncogenic drivers across a wide range of modalities, each with the potential to be best- or first-in-class.
pipeline-best-in-class
Image of Circles

Programs Spanning A Range Of Indications And Platforms.

 
 

Our Differentiated Oncology Assets

By identifying high-impact targets, then pursuing the right modality, we've built a diversified pipeline of assets ranging from engineered proteins to monoclonal antibodies, as well as kinase inhibitors and protein degraders, each with the potential to be best or first in its class.
 
CLN-619
Anti-MICA/B antibody
Phase 1
 
Solid tumors
Multiple Myeloma
Status:
Initial combo data and monotherapy update in 2Q24; Disease specific expansion data in 1H25
CLN-978
CD19xCD3 T-cell engager
Phase 1
 
B-cell NHL
Status:
Phase 1 study ongoing

Zipalertinib (CLN-081/TAS6417)

EGFRex20ins inhibitor
Phase 2
 
NSCLC with exon 20 insertion mutations 2+ line
NSCLC with exon 20 insertion mutations frontline
Status:
Pivotal Phase 2b 2L+ study enrolled  by YE24; Phase 3 1L study actively  enrolling
CLN-049
FLT3xCD3 T-cell engager
Phase 1
 
R/R AML, MDS
Status:
Clinical update from ongoing Phase 1 study in 2H24
CLN-418
B7H4x41BB bispecific immune activator
Phase 1
 
Multiple solid tumors
Status:
Clinical update from ongoing Phase 1 study in 2H24
CLN-617
Collagen-binding IL-12-IL2 fusion protein
Phase 1
 
Pan-cancer
Status:
Phase 1 study ongoing

Early Programs

Powered by our novel research model and with patient benefit as our priority, we innovate without borders, applying rigorous early experimentation to fast-track only the most promising assets to the clinic and ultimately commercialization. Early programs we're currently exploring include:
  • T-cell Receptor (TCR) – A novel T cell engager targeting a senescence and cancer-related pHLA complex.
  • HPK1 Targeting – A potential first-in-class protein degrader that acts as a negative regulator of T cells and TCR signaling.

Harnessing Science for Patient Benefit

Our clinical trials are designed with clinically relevant endpoints and predefined benchmarks for success.